Serialisation: When quick fixes disappoint

Many manufacturers and contract packagers had to learn it the hard way: serialisation is much more than just placing serial numbers on pharmaceutical packaging. During the FMD implementation rush, some companies relied on quick solutions. However, quick fixes did not live up to what they promised and gave manufacturers manifold reasons for disappointment, from lack of interoperability and compliance issues to high operational complexity, to name just a few.

read more

Video: Traceable Quality System

VISIT THE INNOVATION CENTRE

TQS Technology Highlights

With its Traceable Quality System, WIPOTEC-OCS supports pharmaceutical manufacturers in achieving compliance with serialisation and Track & Trace regulations in the EU and many different countries worldwide. The company has developed a broad range of high-quality serialisation and aggregation solutions that, due to their modular design, can be highly customised to any application requirements. Pharmaceutical manufacturers and packagers worldwide appreciate these solutions for their flexibility, high-level interoperability and standardised interfaces.

read more

Improving supply chain transparency through aggregation

Forward-thinking pharmaceutical companies that have already equipped their lines with serialisation technology can even trace the movement of their products in the supply chain by deploying aggregation. Enhanced product traceability enabled through aggregation helps companies prevent product diversion by automating data exchange between the manufacturer and their trade partners. Especially in times of crisis, such as the current COVID-19 pandemic, aggregation is more relevant than ever. Reliable distribution of pharmaceuticals depends on supply chain transparency and automated data flows. Additionally, aggregation improves the decommissioning of shipping cases and pallets, as well as facilitating efficient product recalls or returns. What is more, aggregation is an integral part of a go-to-market strategy for manufacturers who intend to export pharmaceuticals to countries requiring track and trace, for example, Russia, Turkey, the US or China.

To find out in more detail about the benefits of aggregation for pharmaceutical companies, and see what countries require or plan to mandate aggregation, read the related white paper.

download the white paper

About WIPOTEC-OCS

WIPOTEC-OCS is a sales and service company for dynamic, high-precision weighing, inspection solutions, serialisation and Track-& Trace technology. As a wholly owned subsidiary of the high-tech specialist WIPOTEC, which develops and produces all machinery solutions at its headquarters in German Kaiserslautern, WIPOTEC-OCS has been setting global standards in the production lines of leading manufacturers for more than 30 years.

Enabling serialisation while maintaining high production efficiency is one of the significant advantages of the time-tested Track-&-Trace solutions. More than 3,000 manufacturers across every continent trust in the company’s know-how, technological leadership and passion for innovating.

The company keeps its finger on the pulse of the global regulatory requirements to ensure timely updates of its solutions according to the latest requirements in any country worldwide. As an official GS1 Solution Partner, the company is taking an active role in shaping compliance provisions and providing technical guidance and support on their technical implementation. As a member of the OPEN-SCS working group, the company is committed to the standardisation of communication interfaces between different serialisation and data management systems.

GET IN TOUCH NOW

Go to article: Home | Under the microscopeGo to article: In this issueGo to article: SHL Medical Company InsightGo to article: SHL MedicalGo to article: ContentsGo to article: MimotopesGo to article: NewsGo to article: VEGA AustraliaGo to article: Covid-19 executive briefing by GlobalDataGo to article: WipotecGo to article: Nasal spray vaccine for Covid-19Go to article: Datwyler Company Insight Go to article: DatwylerGo to article: Covid-19 clinical trials continue to rise in BrazilGo to article: BiogazelleGo to article: AstraZeneca’s Phase I / II Covid-19 vaccine trial Go to article: SwiftpakGo to article: MTPA resumes screening and enrolment for global Phase III clinical trial of MT-1Go to article: Biesterfeld Go to article: The pharma industry briefingGo to article: From antitoxins to Covid-19 drugs: charting the history of antibody drugsGo to article: Quality control: pharma manufacturing inspections explainedGo to article: Molnár-Institute Company InsightGo to article: Molnar-InstituteGo to article: Oxytocin: the therapeutic potential of the ‘love hormone’Go to article: AI-enabled risk detection in pharma manufacturingGo to article: Dr. Paul LohmannGo to article: Addressing the long-term effects of Covid-19Go to article: Eyes on the prize: the latest in retinitis pigmentosa gene therapiesGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: Breaking the taboo: disrupting the fertility sectorGo to article: Neutralising the gluten threat: are we on the cusp of a coeliac disease breakthrough? Go to article: Nolato Company Insight Go to article: NolatoGo to article: Pharmacovigilance case intake: why the hesitation to automate?Go to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: Zenatek Go to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: EventsGo to article: Next issue